EX-99.2 3 amrn-ex99_2.htm EX-99.2

Investor Presentation JANUARY 2022 a new paradigm in preventative cardiovascular care Exhibit 99.2

Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic product launch, intellectual property, cash flow, research and development, and other statements that are forward-looking in nature and depend upon or refer to future events or conditions, including financial guidance and milestones. These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the “Risk Factors” section in Amarin’s most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin. This presentation is intended for communication with investors and not for drug promotion. AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.

VISION... ...to stop heart disease from being a leading cause of death For 30 years, the focus has been on lowering LDL cholesterol. Statins have reduced LDL with success and still serve a critical purpose, but they are not the complete solution. Elevated triglycerides are also an important marker to identify cardiovascular risk. A 3 Now is the time to Act on CVD

EVERY 36 SECONDS in the US1 ~60M with CVD in Europe4 523M living with CVD globally6 $1.1tn Estimated economic burden by 20352 €210BN annual spending on CV disease management4 ~18M CVD deaths globally in 20196 44M patients Are projected to be on statins3 >4M People die each year from CVD in the European WHO region5 China alone 290M WITH CVD and the leading cause of death7 US CVD BURDEN EUROPE CVD BURDEN INTERNATIONAL CVD BURDEN Cardiovascular Disease (CVD) Is an Enormous and Worsening Public Health Burden 1 Heart Disease and Stroke Statistics—2021 Update; ACC 2 Cardiovascular Disease: A Costly Burden for America Projections Through 2035; 3 IQVIA, Total Patient Tracker, Statin Projected Patient Counts (USC 32110 HMG-COA REDUCTASE INHIB) 12-months ending November 2021, accessed 1/7/2022; 4 European Heart Network A Blue Print for Action on CVD 2020 5 ESC: Cardiovascular Disease Statistics 2019 6 Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 7 China Cardiovascular Diseases Report 2018: An Updated Summary On average someone dies of CVD Leading cause of death globally Increasing prevalence High and increasing economic burden

Placebo groups from multiple recent trials show high P-CVR despite statin-based standard-of-care; 14.6% to 34.7% of patients treated for LDL-C, but not for P-CVR, experienced a major adverse cardiovascular event (MACE) in 3-7 Years. Years of follow up All statin-treated patients had well controlled LDL-C levels (ranging from 67-92 mg/dL*) IMPROVE-IT: 34.7% of statin-treated patients had a MACE at 7 years3 REDUCE-IT®: 28.3% of statin-treated patients had a MACE at 5 years2 FOURIER: 14.6% of statin-treated patients had a MACE at 3 years1 Patients with an event, %* 3 5 7 Cross-trial comparisons are subject to differences in populations, primary outcomes, and other trial design aspects 20 10 30 0 Controlled LDL-C doesn’t eliminate CV risk; P-CVR often remains; 25%-35% lowering major adverse CV events (MACE) shown in CV outcome studies of statin therapies. P-CVR – Persistent Cardiovascular Risk LDL-C control 25–35% Lowering LDL-C Helps But is Not Enough for Many Patients Note: FOURIER, REDUCE-IT® and IMPROVE-IT trials evaluated evolocumab, icosapent ethyl and ezetimibe / simvastatin, respectively * 67 mg/dL is equivalent to 0.8 mmol/L and 92 mg/dL is equivalent to 1.0 mmol/L 1. Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722; 2. Bhatt DL, et al; for REDUCE-IT® Investigators. N Engl J Med. 2019;380(1):11-22; 3. Cannon CP, et al. N Engl J Med. 2015;372(25):2387-2397 Persistent risk beyond LDL-C control 65–75%

CV drug development: A CHALLENGING endeavor SUCCEEDING in a challenging environment Many biopharma abandoned drug development in CV Requirements for long-term outcomes studies evaluating thousands of patients take years to fulfill With REDUCE-IT®, developed the first and only approved medication for reducing cardiovascular risk beyond LDL lowering therapies in certain high-risk, statin- treated, patients Received an US FDA approval with unanimous Advisory committee positive vote of 16:0 Received European Medicines Agency (EMA) approval for a broad label in-line with the REDUCE-IT evidence Significant costs to fund the commercial infrastructure needed for broad primary care reach 6 AMARIN

VASCEPA/VAZKEPA has Demonstrated CV Risk Reduction Beyond Standard-of-Care (including Statins) in Landmark CVOT HR = hazard ratio; NNT = number needed to treat 1. Bhatt DL et al; for REDUCE-IT® Investigators. N Engl J Med. 2019;380(1):11-22 HR = 0.80 (95% CI, 0.66-0.98) P=0.03 CV Death 20% RRR HR = 0.72 (95% CI, 0.55-0.93) P=0.01 Stroke Fatal/Nonfatal 28% RRR HR = 0.69 (95% CI, 0.58-0.81) P<0.001 MI Fatal/Nonfatal 31% RRR Other Secondary Endpoints HR = 0.74 (95% CI, 0.65-0.83) P=0.0000006 26% RRR NNT=28 Key Secondary Endpoint 3-Point MACE CV death, nonfatal MI, or nonfatal stroke Primary Endpoint 5-Point MACE CV death, nonfatal MI, nonfatal stroke, coronary revascularization, or UA requiring hospitalization HR = 0.75 (95% CI, 0.68-0.83) P=0.00000001 25% RRR NNT=21 RR = 0.70 (95% CI, 0.62-0.78) P=0.00000000036 Total Primary Endpoint Events (first and recurring) Composite of CV death, MI, stroke, coronary revascularization and unstable Angina (UA) 30% RRR Significant reductions across the prespecified testing hierarchy 1 Generally consistent reductions across subgroups Analyses suggest lipid, lipoprotein, and inflammatory markers (including TG) likely have limited contribution to the overall CV benefit demonstrated with icosapent ethyl (IPE) Analysis suggests CV benefit derived from multifactorial effects of icosapent ethyl administered at high levels Well-tolerated safety profile with overall adverse event rates similar for both VASCEPA and placebo patients as per US FDA, Health Canada, and European Commission approved labels for VASCEPA/VAZKEPA and peer-reviewed publication

VASCEPA/VAZKEPA Has the Lowest NNT Among New Therapies Proven to Reduce MACE When Added to Current Standard-of-Care Statin monotherapy On top of statin therapy *Based on primary composite endpoints of each trial Note: Cross-trial comparisons are subject to differences in populations, primary outcomes, study duration and other trial design aspects. Information provided for context only; none of the products have same indication as Vascepa® 1. LaRosa JC, et. al., N Engl J Med 2005;352:1425-35; 2. Cannon CP, et al. N Engl J Med. 2015;372(25):2387-2397; 3. Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722; 4. Bhatt DL et al; for REDUCE-IT® Investigators. N Engl J Med. 2019;380(1):11-22 NNT1 45 Lipitor® TNT2006 4.9 years 22% RRR MACE1 NNT2 50 Zetia® IMPROVE-IT2015 7.0 years 6% RRRMACE2 NNT3 67 Repatha® FOURIER2017 2.2 years 15% RRRMACE3 NNT4 Vascepa® (IPE) REDUCE-IT®2018 4.9 years 21 25% RRR MACE4 NNT: Number of patients who need to be treated to prevent one additional bad outcome Results on left are based on first occurrence of MACE*; VASCEPA/VAZKEPA in total events analysis (first and recurring MACE) resulted on average in 1 fewer MACE per 6 patients treated

VASCEPA/VAZKEPA is a Preventative Cardiovascular (CV) Care Treatment Option Beyond LDL-C Lowering VASCEPA/VAZKEPA is the only drug proven to reduce persistent CV risk in the population studied (P-CVR) Pre-Statin Statin Before 1987 Modest LDL-C or HDL-C 1987 and beyond Aggressive LDL-C “Lower is Better” 2020 and beyond Attacking persistent CV Risk (P-CVR), the risk beyond LDL-C lowering Niacin Statins PCSK-9 Inhibitors Ezetimibe Bempedoic acid Fibrates Bile acid sequestrants

Broad Third-Party Support for Icosapent Ethyl American Association of Clinical Endocrinologists Chinese Society of Cardiology Brazilian Society of Cardiology American College of Endocrinology American College of Cardiology American Diabetes Association American Heart Association American Stroke Association Canadian Cardiovascular Society Committee, in collaboration with the Canadian Stroke Consortium Chinese Journal of Internal Medicine (a journal of the Chinese Medical Association) Canadian Stroke Best Practice Recommendations Advisory Chinese Association of Cardiovascular Surgeons (CACS) Chinese Society of Thoracic and Cardiovascular Surgery (CSTCVS) Diabetes CardioRenal Metabolic Diseases (DCRM) Task Force European Society of Cardiology Egyptian Heart Journal Endocrine Society Colombian Society of Cardiology & Colombian Association of Endocrinology, Diabetes and Metabolism European Association of Preventive Cardiology European Atherosclerosis Society Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy (SFSN PTK) Japanese Circulation Society Saudi National Diabetes Center 20+ leading medical societies recognizing importance of Icosapent Ethyl: National Lipid Association Thrombosis Canada The Institute for Clinical and Economic Review (ICER) confirms the cost effectiveness of Vascepa across all of the non-profit organization’s analyses, based on its Quality-adjusted life year (QALY) metrics of <$50,000. October 2017

Before 2021; Mostly R&D and US Commercial Focus 2021 and Beyond: Expanding to Europe and International US EUROPE INTERNATIONAL APPROVED Approved for lowering cardiovascular risk (2019) and treating severe hypertriglyceridemia (original niche indication – 2012) APPROVED for lowering cardiovascular risk (2021) Gain access to ~20 ADDITIONAL COUNTRIES to reach the top 50 cardiometabolic markets in the world CANADA: LAUNCHED via partner in 2020 CHINA Submission accepted - anticipated decision in the second half of 2022 MIDDLE EAST: LAUNCHED via distributor in select countries for TG lowering; now pursuing P-CVR indications INITIATING regulatory filing processes for Australia, New Zealand, Israel plus up to 3 others in 2022 10 YEAR regulatory data protection period – no direct competitor LAUNCHED in Germany Sept 2021 Available for private prescribing prior to launch in other EU markets Market access dossiers filed in 10 COUNTRIES FY21 net revenue expected to approximate ~$575 MILLION (unaudited) Limited GENERIC competition Significant Growth Opportunity for VASCEPA/VAZKEPA Launches throughout Europe expected in 2022

Amarin Future Growth Strategy AMARIN

Full Year 2021 Financial Highlights Total full year 2021 revenue, net expected to approximate $580 million (unaudited), compared with $614.1 million in 2020 U.S. VASCEPA retained 80% and 86% of the IPE market, as per Symphony Health data in the three months and eleven months ended November 30, 2021, respectively ~$490 million in cash and investments and no debt Strong balance sheet to support growth and expansion plans Source: Symphony Health Solutions, November, 2021 Amarin Total Revenue by quarter

Amarin go-to-market Expanding Healthcare Provider Engagement: 3-4 X amplification of physicians reach through digital channels Sales force optimization to focus on the most productive and accessible territories Managed Care Access Enhancement: Drive incremental volume growth through further removing barriers to VASCEPA Rx to ensure that patients in need of CV risk reduction receive proper therapy Optimizing VASCEPA Prescriptions for CV Risk Reduction: Address gaps in prescribing ecosystem to reduce inappropriate generic substitution Evaluating various innovative solutions designed to better manage IPE Rx for CVRR 1 2 3 reached > 150,000 HCPs Via Omnichannel 40% of total Commercial & Medicare Part D lives1 have VASCEPA as the partnered with BlinkRx providing an enhanced, digital-first prescription fulfilment channel, that eliminates the challenges for patients in starting and remaining on VASCEPA 1. As of December 2021 and on weighted average basis 14 AMARIN STRATEGYto drive growth in the US exclusive IPE product

Early signals of the impact of our new Go-To-Market Strategy New to Brand (NTB) growth being led by Branded VASCEPA– Up 8% in recent 4 weeks reaching pre-generic level – Total IPE up 5% Cardiology, Primary Care and Endocrinology all contributing to NTB growth Importantly, Cardiology showing consistent growth up 12% in recent 4 weeks VASCEPA New to Brand Rx Source: Symphony Prescriber Source Data, WE 12/17/2021 NTB: Patients with first fill in 12-months time period for product. 15

VAZKEPA in Europe December 2020 Regulatory approval No Reimbursement None Infrastructure None Medical Education Limited Supply Chain Solid manufacturing network & 3PL agreement Marketing Strategy Initial Planning Team Recruitment of core team ~10 December 2021 EMA & MHRA 10 market dossiers submitted On-going constructive discussions with all health authorities EU commercial hub established in Zug, Switzerland Key financial, legal and compliance processes in place Medical Directors and MSL driving significant medical education programs across Europe, with the most influential national and European opinion leaders Signed contracts with wholesalers in Germany, UK, Italy & the Nordics Go to market strategy, content engine, digital capabilities and CRM foundations ready for 2022 launches ~ 250 Associates ACHIEVEMENTS AMARIN 16

Europe Outlook 2022: Filed market access dossiers in ten key EU countries ahead of YE schedule Reimbursement decisions expected in up to 8 countries The launch of VAZKEPA in up to 6 countries Plans to file next wave of five market access dossiers in 2022 Execution of several agreements in Central & Eastern European markets with partners who already have established infrastructure in such markets 4M deaths per year in Europe WHO ~€210B annual CVD costs to European Union2 10+years of market exclusivity in Europe ESC: Cardiovascular Disease Statistics 2019 European Heart Network. European Cardiovascular Disease Statistics 2017. https://ehnheart.org/cvd-statistics/cvd-statistics-2017.html. Accessed January 2022 Significant Market Opportunity region due to CVD1

Launched VAZKEPA in Germany Relentless focus on education, awareness & access World class scientific launch, scientific media resonance and recognition (Galenus von Pergamon prize finalist) Short Pre-Launch and Covid resurgence, leading to an average frequency of 2.6 in our targeted doctors VAZKEPA volume uptake benchmark comparable to other CV medicines recently launched* Note : Spec Field Force in field since Feb 21, and PCP since Apr 21 *Note : Normalized volume uptake curves relative to peak year sales of the Analogs to ensure comparability Standard Packs

Partnering to Unlock Revenue Potential in ~20 Additional Markets Internationally EU US sNDA Approved Dec. 20191,2  China / HK MENA Approved in Lebanon (Mar. 2018), UAE (Jul. 2018), Qatar (Jan. 2020), Bahrain (Nov. 2020)  Mexico Russia Australia Brazil Japan India Direct launch Partnered Unpartnered3 ROW (select regions with significant opportunity highlighted) 1 For cardiovascular risk reduction indication; 2 For severe hypertriglyceridemia indication; original U.S. NDA approval in July 2012; Canada NDS Approved1 Dec. 2019  EC Approved April 2021 

Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patent approval will vary between market to market. Plans to Bring Unique Cardioprotective Benefits of VASCEPA/VAZKEPA to 20 Additional Markets 1st Wave 2022 2nd Wave 2023 Supported by REDUCE-IT Study and U.S. FDA and EMA Filings 3rd Wave 2024 6 9 5 Countries Countries Countries Seeking Partnerships in approximately 20 additional Countries Representing Potential ~$1B Opportunity AMARIN

VASCEPA/VAZKEPA Life Cycle Management Progress AS A RESULT OF THE LCM EFFORT to enhance our offering to patient in need of reducing their Cardiovascular Risk And in-line with our cardiovascular outcome label where icosapent ethyl is used on top of a statin AMARIN IS INITIATING the development of a fixed dose combination product that has the two components in one

Amarin Strengthens its Executive and Board Leadership: 4 New Executive Members Laurent Abuaf Senior Vice President & President of Europe August 2021 Jason Marks Chief Legal Officer & Corporate Secretary August 2021 Alan Wills Executive Vice President Corporate Business Development November 2021 Lisa DeFrancesco Senior Vice President Investor Relations February 2022 New Board Member Per Wold-Olsen Board Member January 2022

Amarin: An Exciting Opportunity to Create Value US EUROPE FUTURE INTERNATIONAL Grow and defend VASCEPA despite generics’ presence on the market for the VHTG indication Advance the Go-to-Market digital omnichannel model to drive greater awareness and demand Development of fixed dose combination – icosapent ethyl and a statin Build awareness of VAZKEPA across EU as we prepare for strong sequenced launches in key markets throughout 2022 Value based proposed list price of ~€200 or $240 monthly Regulatory filings, approvals and potential launches of VASCEPA, via partners, in up to six new countries, including Australia, New Zealand, and some Asia-Pacific markets Final regulatory actions on VASCEPA in Mainland China and in Hong Kong in second half of 2022 Seek partnerships and opportunities to leverage growing global commercial infrastructure and competent R&D team

Investor Presentation JANUARY 2022